Neurocrine Biosciences, Inc. (NB3.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:01AM CEST
| Previous Close | 126.35 |
| Open | 134.15 |
| Bid | 129.30 x 50000 |
| Ask | 129.70 x 50000 |
| Day's Range | 134.15 - 134.15 |
| 52 Week Range | 83.18 - 135.35 |
| Volume | |
| Avg. Volume | 14 |
| Market Cap | 13.493B |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 58.07 |
| EPS (TTM) | 2.31 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 122.19 |
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements
Neurocrine Biosciences Reports Robust Financial Performance and Pipeline Progress
Investor's Business DailyWhy Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Neurocrine stock rose Wednesday after the leading biotech topped Wall Street's sales expectations and wrapped a key regulatory filing.
ZacksNeurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
© 2024 Yahoo. All rights reserved.